A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.

At a glance
Trial Overview
Trial Details
Interventions
Trial History
References

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FB-102 (Primary)
Indications Vitiligo
Focus Adverse reactions; Therapeutic Use
Sponsors Forte Biosciences

Most Recent Events

09 Apr 2025 Status changed from planning to not yet recruiting.
03 Apr 2025 New trial record
31 Mar 2025 According to Forte Biosciences media release, company is expecting to dose the first patient in the FB102 vitiligo trial shortly.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com